Spiritus Bioscience
Spiritus Biosciences is focused on improving patient experience through novel drug delivery formulations and technology, aiming to create patentable products for mental health and neuropsychiatric disorders. They are advancing proprietary delivery methods in clinical trials to support safer, more efficient treatments with fewer adverse effects for mental health issues.
Industries
Nr. of Employees
small (1-50)
Products
Proprietary clinical‑stage drug delivery method
A patented or patent-pending drug delivery method developed for use with psychedelic therapeutics, stated to be entering Phase I and Phase II clinical trials.
Proprietary clinical‑stage drug delivery method
A patented or patent-pending drug delivery method developed for use with psychedelic therapeutics, stated to be entering Phase I and Phase II clinical trials.
Services
Contract or collaborative development of novel formulations and final dosage forms for neuropsychiatric and mental health therapeutics, emphasizing patient experience and patentability.
Design and operational support for Phase I and II clinical trials incorporating trial methodologies intended to accelerate data collection and reduce trial costs.
Contract or collaborative development of novel formulations and final dosage forms for neuropsychiatric and mental health therapeutics, emphasizing patient experience and patentability.
Design and operational support for Phase I and II clinical trials incorporating trial methodologies intended to accelerate data collection and reduce trial costs.
Expertise Areas
- Formulation development
- Drug delivery system development
- Early‑phase clinical trial design and operations
- Psychedelic therapeutics for mental health
Key Technologies
- Novel formulation and dosage form technologies
- Drug delivery platform development
- Phase I/II clinical trial methodologies
- Clinical data collection optimization